IL1B and Muckle-Wells syndrome: Previously, we developed an NLR family pyrin domain containing (NLRP)3-inflammasome in a cell-free system to screen for inflammasome targeting drugs and identified ASC-targeting drugs that suppressed IL-1β secretion from peripheral blood mononuclear cells incubated with lipopolysaccharide (LPS), as well as spontaneous IL-1β secretion from the peripheral blood mononuclear cells of a patient with Muckle-Wells syndrome [4].